ResMed is a medical instruments & supplies business based in Australia. ResMed shares (RMD) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. ResMed has a trailing 12-month revenue of around $4.4 billion. If you're looking to buy shares, check out the steps below.
Our top pick for
Low costs
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $21.14 - $36.37 |
|---|---|
| 50-day moving average | $22.7636 |
| 200-day moving average | $29.1892 |
| Target price | $30.79 |
| PE ratio | 25.4 |
| Dividend yield | $1.8 (1.28%) |
| Earnings per share (TTM) | $0.94 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$24.29
| 1 week (2023-11-27) | 5.20% |
|---|---|
| 1 month (2023-11-03) | 4.92% |
| 3 months (2023-09-05) | -0.94% |
| 6 months (2023-06-05) | -26.95% |
| 1 year (2022-12-05) | -27.73% |
|---|---|
| 2 years (2021-12-03) | -32.70% |
| 3 years (2020-12-04) | -12.85% |
| 5 years (2018-12-05) | 59.59% |
Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, ResMed shares trade at around 25x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7467. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 billion (£0.0 million).
The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $4.4 billion |
|---|---|
| Operating margin TTM | 26.22% |
| Gross profit TTM | $2.4 billion |
| Return on assets TTM | 12.22% |
| Return on equity TTM | 23.6% |
| Profit margin | 20.72% |
| Book value | 28.897 |
| Market capitalisation | $34.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 31.19% of net profits
Recently ResMed has paid out, on average, around 31.19% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.28% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 1.28% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about A$1.8 per share.
While ResMed's payout ratio might seem fairly standard, it's worth remembering that ResMed may be investing much of the rest of its net profits in future growth.
The latest dividend was paid out to all shareholders who bought their shares by 8 November 2023 (the "ex-dividend date").
ResMed's shares were split on a 2:1 basis on 12 August 2010. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.
Over the last 12 months, ResMed's shares have ranged in value from as little as $21.14 up to $36.37. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while ResMed's is 0.521. This would suggest that ResMed's shares are less volatile than average (for this exchange).
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
